Beta-score: an Assessment of Beta-cell Function After Islet Transplantation
Overview
Affiliations
Objective: Success after islet transplantation can be defined in terms of insulin independence, C-peptide secretion, or glycemic control. These measures are interdependent and all need to be considered in evaluating beta-cell function after islet transplantation. For the current study, a composite beta-score was developed that provides an integrated measure of beta-cell function success after islet transplantation.
Research Design And Methods: The proposed scoring system gave 2 points each for normal fasting glucose, HbA(1c), stimulated C-peptide, and absence of insulin or oral hypoglycemic agent use. No points were awarded if the fasting glucose was in the diabetic range, the HbA(1c) was >6.9%, C-peptide secretion was absent on stimulation, or daily insulin use was in excess of 0.24 units/kg. One point was given for intermediate values. The score ranged from 0 to 8 and was correlated with the glucose value 90 min after a standard mixed meal challenge (n = 218) in 57 subjects before and after islet transplantation. The score was also used to follow subjects for up to 5 years after islet transplantation.
Results: The beta-score correlated well with the plasma glucose level 90 min after a mixed meal challenge (r = -0.849, P < 0.001). On follow-up, the beta-score rose after the first transplant and was maintained up to 5 years, demonstrating continuing function of the transplanted beta-cells.
Conclusions: The beta-score provides a simple clinical scoring system that encompasses glycemic control, diabetes therapy, and endogenous insulin secretion that correlates well with physiological measures of beta-cell function. On this basis, it is suitable as an overall measure of beta-cell transplant function. The beta-score gives an integrated measure of beta-cell function as a continuum that may be more useful than simply assessing the presence or absence of insulin independence.
Anazawa T, Marubashi S, Kodama S, Goto M, Maruyama M, Eguchi H Transplant Direct. 2025; 11(3):e1765.
PMID: 39936131 PMC: 11810022. DOI: 10.1097/TXD.0000000000001765.
Wang C, Orr C, Hacker-Stratton J, El-Shahawy M, Omori K, Qi M Cell Transplant. 2025; 34:9636897241310989.
PMID: 39881535 PMC: 11780635. DOI: 10.1177/09636897241310989.
Moon J, Lee Y, Jeong S, Jun H, Hoang M, Jo Y Stem Cell Res Ther. 2024; 15(1):374.
PMID: 39443977 PMC: 11515471. DOI: 10.1186/s13287-024-03971-2.
Zhao Q, Li J, Lin Z, Tang Y, Yang D, Qin M Ann Surg. 2024; .
PMID: 39247951 PMC: 11723485. DOI: 10.1097/SLA.0000000000006526.
Exploiting in silico modelling to enhance translation of liver cell therapies from bench to bedside.
Ashmore-Harris C, Antonopoulou E, Finney S, Vieira M, Hennessy M, Muench A NPJ Regen Med. 2024; 9(1):19.
PMID: 38724586 PMC: 11081951. DOI: 10.1038/s41536-024-00361-3.